Arrowhead Pharmaceuticals, Inc. cash flow to debt ratio of 49.02% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Arrowhead Pharmaceuticals, Inc.'s free cash flow has increased -125.96% from $-604.32M last year to $156.89M, signaling increasing performance

Arrowhead Pharmaceuticals, Inc.'s debt to equity ratio is 1.86, which means that the company's assets are unhealthy financed, signaling financial risk.

Arrowhead Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 4.59 last year to 1.86 today, signaling strengthened financials

Arrowhead Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Arrowhead Pharmaceuticals, Inc.'s interest coverage ratio is -2.45, which means that the company struggles to meet interest obligations, signaling financial risk.

Arrowhead Pharmaceuticals, Inc.'s profit margin has increased (-99.72%) in the last year from -16.88K% to -47.79%, signaling increasing performance

Arrowhead Pharmaceuticals, Inc.'s short-term assets of $950.64M exceed its short-term liabilities of $195.49M

Arrowhead Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Arrowhead Pharmaceuticals, Inc.'s return on equity of -60.54%, is lower than 15.00%, indicating bad performance

Arrowhead Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Arrowhead Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Arrowhead Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Arrowhead Pharmaceuticals, Inc. has a free cash flow yield of 1.26%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Arrowhead Pharmaceuticals, Inc.'s yearly earnings has increased -99.73% since last year from $-599.49M to $-1.63M, signaling increasing performance

Arrowhead Pharmaceuticals, Inc.'s yearly revenue has increased 23.26K% since last year from $3.55M to $829.45M, signaling increasing performance

ROIC -12.12% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Arrowhead Pharmaceuticals, Inc.'s 3-year revenue CAGR of 50.52% is positive, indicating growing revenue over the past 3 years

Arrowhead Pharmaceuticals, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Arrowhead Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Arrowhead Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Arrowhead Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arrowhead Pharmaceuticals, Inc. is overvalued relative to its fair value price of 7.25 based on EBITDA multiple model

Arrowhead Pharmaceuticals, Inc. has an EV/EBITDA ratio of 72.13x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Arrowhead Pharmaceuticals, Inc. is overvalued relative to its fair value price of -102.21 based on Earnings Fair Value model

Arrowhead Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arrowhead Pharmaceuticals, Inc. has a price-to-book ratio of 27.18x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Arrowhead Pharmaceuticals, Inc. has a price-to-sales ratio of 18.92x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue